| ГОМК | Брадикардия, гипотензия |
| Кокаин [70] | пароксизмальная предсердная тахикардия, гипертензия, синдром внезапной смерти в результате прямой кардиотоксичности |
| Экстази (MDMA) [71] | Гиперетензия, сменяющаяся гипотонией, спонтанное кровотечение, тахикардия, желудочковая аритмия |
| Этанол [72] | Выраженная брадикардия с нарушением функции сердца |
| Опиаты (героин) [73] | Синусовая бради- и тахикардия, гипо- и гипертензия, сердцебиения, обмороки |
| Метамфетамин [74] | Предсердно-желудочковая аритмия, гипертензия, боль в груди, миокардиальная ишемия, сердцебиения |
Таблица 4. Влияние ГОМК и других препаратов на дыхательную систему
| GHB | Угнетение дыхания |
| Cocaine | Дыхание Чейна-Стокса |
| Ecstasy (MDMA) | Угнетение дыхания |
| Ethanol | Угнетение дыхания |
| Heroin/Opiate | Угнетение дыхания, ЧДД менее 12 |
| Methamphetamine | Диспноэ |
Список литературы
1. Okun M, Bartfield RB, Doering PL. GHB Toxicity: What You Need to Know. Emergency Medicine 2000:10-23.
2. Zvosec DL, Smith SW, McCutcheon BS, Spillane J, Hall BJ, Peacock EA. Adverse events, including death associated with the use of 1, 4-butanediol. New Eng J Med 2001;344(2):87-94.
3. Weir E. Raves: a review of the culture, the drugs, and the prevention of harm. Can Med Assoc J 2000;162(13):1843-48.
4. Schwartz RH, Milteer R. Drug-facilitated sexual assault (`Date Rape'). South Med J 2000;93(6):558-61.
5. O'Connell T, Kaye L, Plosay JJ. Gamma-hydroxybutyrate (GHB): A newer drug of abuse. American Family Physician 2000;62(11):2478-83.
6. Shannon M, Quang LS. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1, 4-butanediol: a case report and review of the literature. Pediatr Emer Care 2000;16(6):435-40.
7. Eggert MS, Waldrum MR. Gamma-hydroxybutyrate intoxication with respiratory failure: A still growing epidemic amoung adolescents and young adults. Chest 2000;118(4):88s-9s.
8. Timby N, Eriksson A, Bostrom K. Gamma-hydroxybutyrate-associated deaths. Am J Med 2000;108(6):518-19.
9. Tunnicliff G. Sites of action of gamma-hydroxybutyrate- A neuroactive drug with abuse potential. J Toxicol Clin Toxicol 1997; 35(6): 581-90.
10. Snead OC. Gamma-hydroxybutyrate in the monkey, electroencephalographic, behavioral, and pharmacokinetic studies. Neurology 1978;28(7):636-42.
11. Maitre M. The gamma-hydroxybutyrate signalling system in the brain: organization and functional implications. Prog Neurobiol 1997;51(3):337-61.
12. Gamma-hydroxybutyrate use- New York and Texas, 1995-1996. MMWR Morb Mortal Wkly Rep.1997;46(13):281-83.
13. Adverse events associated with ingestion of gamma-butyrolactone-Minnesota, New Mexico, and Texas, 1998-1999. MMWR Morb Mortal Wkly Rep.1999;48(7):137-40.
14. Louagie HK, Verstraete AG, De Soete CJ, Baetens DG, Calle PA. A sudden awakening from near coma after combined intake of gamma-hyroxybutyrate and ethanol. J Toxicol Clin Toxicol 1997;35(6):591-94.
15. Bourguignon JJ, Schoenfelder A, Schmitt M, Wermuth CG, Hechler V, Charlier B, Maitre M. Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem 1988;31(5):893-97.
16. Snead OC. Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. J Neurochem 2000;75(5):1986-96.
17. Hosli L, Hosli E, Lehmann R, Schneider J, Borner M. Action of gamma-hydroxybutyrate and GABA on neurones of cultured rat central nervous system. Neurosci Lett 1983; 37(3):257-60.
18. Feigenbaum JJ, Howard SG. Gamma-hydroxybutyrate is not a GABA agonist. Prog Neurobiol 1996;50(1):1-7.
19. Mathivet P, Bernasconi R. Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABA B receptor agonist. Eur J Pharmacol 1997;321(1):67-75.
20. Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. 1997;92(1):89-96.
21. Doherty J, Hattox S, Snead O, Roth R. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig, and rhesus monkey brain. J Pharmacol Exp Ther 1978;207(1):130-9.
22. Hedou G, Chasserot-Golaz S, Kemmel V, Gobaille S, Roussel G, Artault JC, et al. Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum. J Comp Neurol 2000;426(4):549-60.
23. Howard SG, Feigenbaum JJ. Effect of gamma-hydroxybutyrate on central dopamine release in vivo. A microdialysis study in awake and anaesthetised animals. Biochem Pharmacolo 1997;53(1):103-10.
24. Feigenbaum JJ, Howard SG. Does gamma-hydroxybutyrate inhibit or stimulate central dopamine release? Int J Neurosci.1996;88(1-2):53-69.
25. Madden TE, Johnson SW. Gamma-hydroxybutyrate is a GABA B receptor agonist that increases the potassium conductance in rat ventral tegmental dopamine neurons. J Pharmacol Exp Ther 1998;287(1):261-5.
26. Fiegenbaum JJ, Simantov RG. Lack of effect of gamma-hydroxybutyrate on mu, delta, and kappa opioid receptor binding. Neurosci Lett. 1996;212(1):5-8.
27. Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of gamma-hydroxybutyrate on central dopamine release in vivo in awake animals: a microdialysis study. Neurosci Lett 1997;224(1):71-4.
28. Schmidt-Mutter C, Gobaille S, Muller C, Maitre M. Prodynorphin and proenkephalin mRNSs are increased in rat brain after acute and chronic administration of gamma-hydroxybutyrate. Neurosci Lett 1999;262(1):65-8.
29. Miguez I, Aldegunde M, Duran R, Veira JA. Effect of low doses of gamma-hydroxybutyric acid on serotonin, noradrenaline, and dopamine concentrations in rat brain areas. Neurochem Res. 1988;13(6):531-3.
30. Mamelak M. Gamma-hydroxybutyrate: An endogenous regulator of energy metabolism. Neurosci Biobehav Rev 1989;13(4):187-198.
31. Mamelak M. Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis. J Geriatr Psychiatry Neurol 1997;10(1):29-32.
32. Van Cauter E, Plat L, Scharf M, Leproult R. Simultaneous stimulation of slow wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest 1997;100(3):745-53.
33. Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998;21(5):507-14.
34. Scharf MB, Hauck M, Stover R, McDannold M, Berkowitz D. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol 1998;25(10):1986-90.
35. Entholzner E, Mielke L, Pichlmeier R, Weber F, Scneck H. EEG changes during sedation with gamma-hydroxybutyric acid. Anesthesist 1995;44(5):345-50.
36. Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J. Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993;16(3):216-20.
37. Scrima L, Hartman PG, Johnson FH, Thomas EE, Hiller FC. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: A double-blind study. Sleep 1990;13(6): 479-90.
38. Scrima L, Hartman PG, Johnson FH, Hiller FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989;26(4):329-30.
39. Lapierre O, Montplaisir J, Lamarre M, Bedard MA. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep 1990;13(1):24-30.
40. Mamelak M, Sowden K. The effect of gamma-hydroxybutyrate on the H-reflex: Pilot study. Neurology 1983;33(11):1497-1500.
41. Placement of gamma-butyrolactone in List I of the controlled substances act (21 U.S.C. 802 (34)). Drug Enforcement Administration, Justice. Final Rule. Fed Regist 2000;65(79):21645-7.
42. GHB Slated for FDA Approval in 2001. http://www.ceri.com/GHB2001.htm, accessed May 18, 2001.
43. Peripheral and Nervous System Drugs Advisory Committee, notice of meeting. http://www.fda.gov/OHRMS/DOCKETS/98fr/021401a.htm, accessed May 18, 2001.
44. Orphan Drug Status for GHB, http://www.fda.gov/orphan/designat/list.htm, accessed May 18, 2001.
45. Department of Health and Human Services, Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting. Fed Regist 2001;66(93):24391.
46. Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G et al. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomised comparative study versus benzodiazepine. Alcohol Clin Exp Res 1999;23(10):1596-604.
47. Addolorado G, Castelli E, Stefanini G, Casella G. An open multicenter study evaluating 4-hydroxybutyric acid sodium salt in the medium term treatment of 179 alcohol dependent subjects. Alcohol Alcohol 1996;31(4):341-5.
48. Gallimberti L, Canton G, Gentile N, Ferri M. Gamma-hydroxybutyric ccid for the treatment of alcohol withdrawal syndrome. Lancet 1989;30,2(8666):787-9.
49. Beghe' F, Carpanini MT. Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol-dependent patients. Alcohol 2000;20:223-5.
50. Gessa GL, Agabio R, Carai MA, Lobina C, Pani M, Reali R et al. Mechanism of the antialcohol effect of gamma-hydroxybutyric acid. Alcohol 2000;20:271-6.
51. Rosen MI, Pearsall HR, Woods SW, Kosten TR. The effects of gamma-hydroxybutyric acid in opioid-dependent patients. J Subst Abuse Treat 1997;14(2):149-54.
52. Rosen MI, Pearsall HR, Woods SW, Kosten TR. The effects of gamma-hydroxybutyric acid in naloxone-precipitated opiate withdrawal. Neuropsychopharmacology 1996;14(3):187-93.
53. Gallimberti L, Schifano F, Forza G, Miconi L, Ferrara SD. Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal. Eur Arch Psychiatry Clin Neurosci 1994;244(3):113-4.
54. Gallimberti L, Cibin M, Pagnin P, Sabbion R, Pani PP, Pirastu R et al. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology 1993;9(1):77-81.
55. Gamma-hydroxybutyrate poisoning. The Medical Letter 1991;33(836):8.
56. Snead OC. Gamma-hydroxybutyric acid seizures bear no relation to core temperature. Epilepsia 1990;31(3):253-8.
57. Hoes MJ, Vree TB, Guelen PJ. Circadian rhythm in plasma concentrations of gamma-hydroxybutyric acid in alcoholics. Int J Addict 1981;16(6):1071-5.
58. Snead OC. Gamma-hydroxybutyrate in the monkey. Effect of intravenous anticonvulsant drugs. Neurology 1978;28(11):1173-8.
59. Hechler V., Ratomponirina C, Maitre M. Gamma-hydroxybutyrate conversion into GABA induces displacement of GABA B binding that is blocked by valproate and ethosuximide. J Pharmacol Exp Ther 1977;281(2):753-60.
60. Addolorato G, Caputo F, Capristo E, Gasbarrini G. Diazepam in the treatment of GHB dependence. Br J Psych 2000;177:181.
61. Price G. In-patient detoxification after GHB dependence. Br J Psych 2000;177:181.
62. Catalano MC, Glass JM, Catalano G, Burrows SL, Lynn WA, Weitzner BS. Gamma-butyrolactone (GBL) withdrawal syndromes. Psychosomatics 2001;42:1.
63. Yates W, Viera AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc 2000;75(4):401-2.
64. Henderson, R., Holmes, C. Reversal of the anaesthetic action of sodium gamma-hydroxybutyrate. Anaesth Intensive Care 1976;4(4):351-4.
65. Cadicott DG, Kuhn M. Gamma-hydroxybutyrate overdose and physostigmine: Teaching new tricks to an old drug? Annals of Emergency Medicine 2001;37(1):99-102.
66. Kaasin V, Nagren K, Hietala J, et. al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's Disease. Neurology 2000 Apr 11;54(7):1482-87.
67. Fujita M, Verhoeff NP, Varrone A, et. al. Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 2000 Jan 10;387(2):179-188.
68. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37(2):147-53.
69. Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000;18(1):65-70
70. Pearman K. Cocaine: a review. J Laryng Otol. 1979;93:1191-99.
71. O’Connor B. Hazzards associated with the recreational drug ‘ecstasy’. Br J Hosp Med. 1994;52(10):507-14.
72. Speigelman R. Treatment of ethanol intoxication. Drug Info Bull. 1980;14(2):1-3.
73. Sporer KA. Acute heroin overdose. Ann Int Med. 1999;130(7):584-90.
74. Derlet RW, Heischober B. Methamphetamine: stimulant of the 1990s?. Wes J Med. 1990;153(6):625-27.